Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where does it say it's rare? Maybe you missed the part about the Flood. LoL Still thousands stranded in the airports. Runways flooded. Vertical fight take offs are in need now. They have the money to speed up production. It will happen again !
I don't think Global warming is going away.
Nice Close Friday.
CLIA Waiver is taking longer than a Spaceship to Mars. Trial that takes 3 weeks to do. Either the FDA or AXIM has a problem. AXIM has no reason for the delay unless they left out some important facts in their story. We know John would never do that. LoL
Someone is crazier than me 1.414,300 Buy order
Call me Crazy Bought another 78000
Dang Can it get any uglier ?
Purchased 70,000 shares today. First part 50,000 filled @ .0431 second part 20,000 filled @ .014105 and shows as a sale. Hmm
Not good for charts when they do that crap.
Bashers sure post here a lot lately. Must be getting close to a RALLY !
Looks like it's about time to Saddle Up
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
9:06 AM ET 2/20/24 | Dow Jones
February, 20, 2024 -- (AXIM Biotech) --
(NewMediaWire)
The Company's Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM's Digital Assay Reader
SAN DIEGO, CA - (NewMediaWire) - February 20, 2024 - AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solutions development company, announced today that the Company has received an additional order for its electronic readers designed to analyze both of the Company's proprietary diagnostics assays from its commercialization partner Verséa Ophthalmics. The re-order of readers marks a pivotal milestone in AXIM's expanding clinical presence and re-occurring revenue opportunity.
AXIM's commercialization partner Verséa Ophthalmics has been ramping up sales of the Company's proprietary, FDA-cleared ocular diagnostic assays in recent months. Both its ocular T-POC TOTAL IgE Immunoassay and T-POC LACTOFERRIN Immunoassay Kits use an electronic reader to analyze the results of tear samples at the point-of-care. Verséa Ophthalmics' reorder of these readers indicates an impending clinical expansion of AXIM's diagnostic program. Most clinics require at least two readers to efficiently perform both tests. Once a clinic receives a reader it must undergo a validation prior to its clinical use. The recent reorder reflects the successful clinical validation and implementation of the reader platform. AXIM expects clinics to perform approximately 150 tests per month. The reorder made by Verséa indicates that they have sold and/or disbursed the majority of their original inventory of readers to clinics and foresees additional interest in the platform from new clinics.
"Sales of our diagnostic platform which is based on a digital reader that allows for quantification of tear biomarkers, demonstrates momentum as shown by this re-order," said John Huemoeller II, CEO of AXIM Biotechnologies. "As Verséa continues to expand sales, we will work with our recently announced manufacturing partner Auer to scale manufacturing to not only meet demand but improve efficiency wherever possible. Our platform was designed to create a re-occurring revenue stream for AXIM as the tests are one-time-use and have associated Medicare CPT codes. The more clinics we are able to add, the more monthly re-occurring revenue is produced for AXIM. We are extremely pleased by the positive reception Verséa Ophthalmic's is getting from clinicians and look forward to fulfilling this re-order quickly, enabling a whole new set of clinics to begin testing on our platform."
Both of AXIM's ocular diagnostic assays were designed to provide clinicians with a tool to both diagnosis and properly treat Dry Eye Disease (DED) at the point-of-care, a previously unavailable solution. The tests quantitatively measure two different indicators in patient tear samples which have been shown to assist clinicians in proper diagnosis of DED, and render result in nine minutes. DED is historically under or mis-diagnosed with estimates that between 5%-15% of the entire US population show symptoms consistent with DED. AXIM's platform seeks to close this diagnosis gap through its affordable, accurate, and point-of-care platform.
For more information on AXIM's diagnostic solutions or to speak with someone at AXIM's commercialization partner Verséa about adding these innovative solutions to your clinic, please visit: https://www.versea.com/divisions/ophthalmics/
About AXIM(R) Biotechnologies
Founded in 2014, AXIM(R) Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com.
Forward-Looking Statements
The statements made by Axim Biotechnologies Inc., in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim's eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company's diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim's SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
CONTACT
AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422
Investor Relations
investors@aximbiotech.com
888-759-0844
Copyright (c) 2024 TheNewswire - All rights reserved.
> Dow Jones Newswires
February 20, 2024 09:06 ET (14:06 GMT)
Looks like there's going be an MJ sector run this year !!! MJNA getting ready!
Sure looks like we'll be testing the 52 week low @ .014. "Loading Zone"
Lots of Happy Campers here. WoW I'm thinking the speculative market players will wait till 2023 year end report before jumping in. That means April. This being an election year I'm sure Marijuana legalization will be up @ Bat. We need a Homerun.
Up 15 % Ask moved to .003 Say What
Sorry I didn't mean LVVV manipulated. I meant outside sources did. Note Holders with a little more knowledge and opportunity than us. "Retail"
I think LVVV has learned their lesson about manipulating the share price, News releases, and stock chat boards lies and has decided the best answer is to shut up and wait for a cash infusion and market sentiment to return to the positive.
**** Looks like there's going be an MJ sector run this year !!! MJNA is experiencing yet another run ( In My Opinion ) LOL
Remember the louder the Bears get the closer we are.
Exactly Right STOP Feeding The BEARS ! They put out a terrible smell. Buy Buy Buy
LVVV ihub is controlled like the stock is I'm so sorry to say.
***** Looks like there's going be an MJ sector run this year !!! MJNA is experiencing yet another run ( In My Opinion ) LOL
Moist cannabis is heavy: Water has weight. Depending on the cultivar, its wet weight (pre-dried) is anywhere from 60-67% heavier than fully dried and cured cannabis. In other words, properly dried and cured cannabis weighs 33-40% of the wet weight at harvest.
What stinks is No Good news is going to stop the short sellers from winning till they decide to take their foot off of the market.
Anyone ever think that Bill doesn't want to dilute just to pay bills while the rich are shorting LVVV to death. As a CEO wouldn't you wait till a market rally if you could.
You don't seem to know just always speculating. Please answer something simple. Why haven't you sold and why are you here if the Companies is embezzling all the money. Somebody has to be stupid to stay in that kind of a stock or are you saving us?
Read the whole article . It Will Make You Sick !!! This is what it's like to live in a Republican controlled State all paid off by Billonaires
The U.S. Hemp Roundtable sent out a call-to-action alert following Monday’s committee vote, imploring supporters to contact their representatives and urge them to oppose the amendment package because it would prohibit the sale of full-spectrum hemp products
During a 30-minute hearing on Monday, the Senate General Government Committee voted 4-1 to attach the cannabis legislation to an unrelated House-passed bill on alcohol regulations
The chairman said the public only had until 2:30pm ET on Monday to submit comment on the cannabis legislation—just hours after it was unveiled and moved through committee during the brief hearing. No additional public testimony will be accepted on Tuesday or Wednesday before a potential vote to send it to the floor.
ttps://www.marijuanamoment.net/ohio-senate-committee-advances-bill-to-eliminate-marijuana-home-grow-reduce-possession-limits-and-raise-taxes-days-before-legalization-takes-effect/
Read the whole article . It Will Make You Sick !!! This is what it's like to live in a Republican controlled State all paid off by Billonaires
The U.S. Hemp Roundtable sent out a call-to-action alert following Monday’s committee vote, imploring supporters to contact their representatives and urge them to oppose the amendment package because it would prohibit the sale of full-spectrum hemp products
During a 30-minute hearing on Monday, the Senate General Government Committee voted 4-1 to attach the cannabis legislation to an unrelated House-passed bill on alcohol regulations
The chairman said the public only had until 2:30pm ET on Monday to submit comment on the cannabis legislation—just hours after it was unveiled and moved through committee during the brief hearing. No additional public testimony will be accepted on Tuesday or Wednesday before a potential vote to send it to the floor.
ttps://www.marijuanamoment.net/ohio-senate-committee-advances-bill-to-eliminate-marijuana-home-grow-reduce-possession-limits-and-raise-taxes-days-before-legalization-takes-effect/
Read the whole article . It Will Make You Sick !!! This is what it's like to live in a Republican controlled State all paid off by Billonaires
The U.S. Hemp Roundtable sent out a call-to-action alert following Monday’s committee vote, imploring supporters to contact their representatives and urge them to oppose the amendment package because it would prohibit the sale of full-spectrum hemp products
During a 30-minute hearing on Monday, the Senate General Government Committee voted 4-1 to attach the cannabis legislation to an unrelated House-passed bill on alcohol regulations
The chairman said the public only had until 2:30pm ET on Monday to submit comment on the cannabis legislation—just hours after it was unveiled and moved through committee during the brief hearing. No additional public testimony will be accepted on Tuesday or Wednesday before a potential vote to send it to the floor.
ttps://www.marijuanamoment.net/ohio-senate-committee-advances-bill-to-eliminate-marijuana-home-grow-reduce-possession-limits-and-raise-taxes-days-before-legalization-takes-effect/
Everything will go up after the retail investor goes broke and in debt over Christmas giving the 1 and 2 % ers a Double play. Cleaning House on Christmas and the end of year rally which will run into next year. Especially with it being an election year. Today timing is more important than ever not a Company PR. Companies have to hold news and time things as we do or fear that shorting will put them out of business or shrink their Company till they wish they were out of Business. JMHO
What is he suppose to do about it? You seem to think you know everything
You got that right Poor us to if your paying attention
How do you tell if your stock is being manipulated?
If the company is generating revenue and has future growth potential, and still the company stocks are plummeting and trading, sometimes as low as its floor, then there's a high chance that the company stocks are being shorted or manipulated.Feb 24, 2022
Hedge funds have an incredible supply of short shares available to borrow. What is this? This advantage has allowed them to manipulate a stock's share price by initiating short-ladder attacks. While supply and demand are pushing a stock's price up, hedge funds short the stock using an insane amount of leverage.Feb 8, 2023
I'm thinking its finally time. 1and 2% er's love to get in as the retail investor runs out of money during the Holidays.
***** Looks like there's going be an MJ sector run this year !!! MJNA is experiencing yet another run ( In My Opinion ) LOL
***** Looks like there's going be an MJ sector run this year !!! MJNA is experiencing yet another run ( In My Opinion ) LOL